TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55
10/1/2026
Impact: 70
Healthcare
TD Cowen has initiated coverage on Teva Pharmaceutical Industries (NYSE: TEVA) with a Buy rating. The firm has set a price target of $55 for the company's stock.
AI summary, not financial advice
Share: